Everything is calm in the pharmaceutical market
Weekly Pharmacy www.apteka.ua
based on the materials of IMS Health Incorporated
The total volume of sales of medicines on the global pharmaceutical market for 12 months – by June 2011 – amounted to 530.7 billion US dollars (according to MAT, Moving annual total). The pharmaceutical markets of such countries as China, Brazil and Argentina demonstrated the maximum rates of development.
Total sales of drugs in the main pharmaceutical markets for 12 months
(July 2010 – June 2011) by June 2011, indicating the percentage of growth
compared to the same period of the previous year.Region/Country
| Pharmaceutical market volume, | billion US dollars∆, compared to |
since July 2009 – June 2010North America: |
| 247,5 | 3% | |
| USA* | 227,9 | 3% |
| Canada | 19,6 | 2% |
| Europe: Top 5 | 111,0 | 1% |
| Germany | 37,6 | 4% |
| France | 28,7 | — |
| Italy | 16,2 | — |
| Spain | 14,5 | 2% |
| Great Britain | 14,0 | 1% |
| Japan** | 93,2 | 3% |
| China | 35,8 | 19% |
| Latin America: Top 4 | 32,5 | 15% |
| Brazil | 20,0 | 19% |
| Mexico | 8,0 | 2% |
| Argentina | 4,5 | 29% |
| Australia/New Zealand | 10,7 | 6% |
| Total | 530,7The total volume of sales of medicines in the global pharmaceutical market by July 2011 amounted to 539.8 billion US dollars (according to the MAT indicator). |
The fastest growing markets among the world are those of Latin America – Venezuela and Argentina (31% and 30%). The markets of China and Brazil also demonstrate high rates of development (18 and 19%, respectively).
Total sales of drugs in the main pharmaceutical markets for the 12 months to July 2011
indicating the percentage increase compared to the same period of the previous year.Region/Country
| Pharmaceutical market volume, | billion US dollars∆, compared to |
since August 2009 – July 2010North America: |
| 248,2 | 3% | |
| USA* | 228,5 | 3% |
| Canada | 19,7 | 2% |
| Europe: Top 5 | 111,6 | 1% |
| Germany | 37,8 | 4% |
| France | 28,9 | — |
| Italy | 16,3 | — |
| Spain | 14,5 | 2% |
| Great Britain | 14,1 | 1% |
| Japan** | 94,1 | 4% |
| China | 36,3 | 18% |
| Latin America: Top 4 | 38,7 | 16% |
| Brazil | 20,5 | 19% |
| Mexico | 8,1 | 2% |
| Venezuela | 5,5 | 31% |
| Argentina | 4,6 | 30% |
| Australia/New Zealand | 10,9 | 6% |
| Total | 539,8*Sales in pharmacies, grocery stores and through postal shipments are included. |
**The data on sales volume in the Japanese market includes the sales volume of the hospital segment.
There are no changes in the pharmacotherapeutic structure of the global pharmaceutical market. Traditionally, the leader in sales volume among the PBX classification groups of the 3rd level were medicines of the C10A group "Hypolipidemic drugs, monocomponent". On the 2nd place is group A02B "Drugs for the treatment of peptic ulcer and gastroesophageal reflux disease"; on the 3rd - N05A "Antipsychotic drugs", on the 4th and 5th – N06A "Antidepressants" and C09C "Simple drugs of angiotensin II antagonists", respectively.
By the volume of sales in monetary terms in the global pharmaceutical market by June 2011, Liprimar®/Lipitor® (atorvastatin) is invariably the leader. On the 2nd, 3rd and 4th lines are Plavix®/Plavix® (clopidogrel), Nexium®/Nexium® (esomeprazole) and Seretide®/Seretide® (fluticasone + salmeterol), respectively. The composition of the top 5 closes Crestor® / Crestor® (rosuvastatin).
The top list in terms of sales in monetary terms among corporations in the global pharmaceutical market also demonstrates stability. During the period under review, it was traditionally headed by Pfizer. Novartis is on the 2nd line. The 3rd, 4th and 5th places were taken by AstraZeneca, Merck &Co. and GlaxoSmithKline, respectively.
Portal "Eternal youth" http://vechnayamolodost.ru28.09.2011